31 July 2021 : Clinical Research
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy
Xingqin Zhou1BCE, Yazhou Chang2BD, Jing Qian1BF, Chaoyan Shen1DEF, Jie Han1EF, Hongyu Zhao1DF, Renan Chang3AG*DOI: 10.12659/MSM.929474
Med Sci Monit 2021; 27:e929474
Table 1 Patients’ characteristics and treatment regimens in the Study Group.
| Variable | FOLFOX4 (n=14) | mFOLFOX6 (n=26) | FOLFIRI (n=14) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 7 (50.0%) | 11 (42.3%) | 8 (57.1%) |
| Female | 7 (50.0%) | 15 (57.7%) | 6 (42.9%) |
| Age (years) | |||
| Median | 65 | 70 | 67 |
| Range | 57–84 | 62–87 | 55–86 |
| Weight (kg) | |||
| Mean | 68.5 | 71.9 | 69.7 |
| SD | 15.3 | 14.5 | 16.6 |
| Height (cm) | |||
| Mean | 167.8 | 169.4 | 165.5 |
| SD | 8.4 | 8.2 | 8.9 |
| Baseline BSA (m) | |||
| Mean | 1.83 | 1.86 | 1.82 |
| SD | 0.20 | 0.18 | 0.19 |
| Pretreatment ECOG status | |||
| 0 | 7 | 15 | 8 |
| 1 | 5 | 8 | 5 |
| 2 | 2 | 3 | 1 |
| Starting infusional 5-FU dose (mg/m) | |||
| Average | 2350 | 2330 | 2520 |
| SD | 158 | 170 | 163 |
| Line of treatment, n (%) | |||
| First-line | 9 | 16 | 7 |
| Second-line | 3 | 6 | 5 |
| Third-line or more | 2 | 4 | 2 |
| SD – standard deviation; FOLFOX – oxaliplatin, folinate, 5-FU; FOLFIRI – irinotecan, folinate, 5-FU. | |||